Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lahn

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Cancer Cell|December 16, 2010
TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human GlioblastomaJudit Anido, Andrea Sáez-Borderías, Alba Gonzàlez-Juncà, et al.
Cancer Research|December 30, 2010
Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinaseLi Zhou, Christine McMahon, Tushar Bhagat, et al.
Investigational New Drugs|March 2, 2011
Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft modelTimothy P Burkholder, Joshua R Clayton, Mark E Rempala, et al.
Oncotarget|February 23, 2018
Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitorJonathan M Yingling, William T McMillen, Lei Yan, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Cancer Cell|December 16, 2010
TGF-β Receptor Inhibitors Target the CD44(high)/Id1(high) Glioma-Initiating Cell Population in Human GlioblastomaJudit Anido, Andrea Sáez-Borderías, Alba Gonzàlez-Juncà, et al.
Cancer Research|December 30, 2010
Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinaseLi Zhou, Christine McMahon, Tushar Bhagat, et al.
Investigational New Drugs|March 2, 2011
Discovery of LY2457546: a multi-targeted anti-angiogenic kinase inhibitor with a novel spectrum of activity and exquisite potency in the acute myelogenous leukemia-Flt-3-internal tandem duplication mutant human tumor xenograft modelTimothy P Burkholder, Joshua R Clayton, Mark E Rempala, et al.
Oncotarget|February 23, 2018
Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitorJonathan M Yingling, William T McMillen, Lei Yan, et al.
Pageof 7